Related Experiment Video
Updated: Apr 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Generic drugs: Review and experiences from South India
1Department of Community Medicine, Pushpagiri Institute of Medical Sciences and Research Center, Tiruvalla, Kerala, India.
Abstract:
The cost of pharmaceuticals, as a percentage of total healthcare spending, has been rising worldwide. This has resulted in strained national budgets and a high proportion of people without access to essential medications. Though India has become a global hub of generic drug manufacturing, the expected benefits of cheaper drugs are not translating into savings for ordinary people. This is in part due to the rise of branded generics, which are marketed at a price point close to the innovator brands. Unbranded generic medicines are not finding their way into prescriptions due to issues of confidence and perception, though they are proven to be much cheaper and comparable in efficacy to branded medicines. The drug inventory of unbranded generic manufacturers fares reasonably when reviewed using the World Health Organization-Health Action International (WHO-HAI) tool for analysing drug availability. Also, unbranded generic medicines are much cheaper when compared to the most selling brands and they can bring down the treatment costs in primary care and family practice. We share our experience in running a community pharmacy for an urban health center in the Pathanamthitta district of Kerala State, which is run solely on generic medicines. The drug availability at the community pharmacy was 73.3% when analyzed using WHO-HAI tool and the savings for the final consumers were up to 93.1%, when compared with most-selling brand of the same formulation.
Related Concept Videos
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence: Overview
Oral Drug Delivery Systems: Continuous-Release Systems
Drug Regulation
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Modified-Release Drug Delivery Systems: Bioavailability

